FDA Approval Insights: Talquetamab in Relapsed/Refractory Multiple Myeloma

0 意见· 09/07/23
OncLive® On Air
0

Dr Minnema discusses the FDA approval of talquetamab in patients with relapsed/refractory multiple myeloma, key data from the MonumenTAL-1 trial, and the importance of designing clinical trials to address unmet patient needs.

显示更多

 0 注释 sort   排序方式


下一个